Skip to main content
S 3862 116th Congress Senate Commerce Cardiovascular and respiratory health Civil actions and liability Consumer affairs Cosmetics and personal care Emergency medical services and trauma care Fraud offenses and financial crimes Health technology, devices, supplies Infectious and parasitic diseases Marketing and advertising

CEASE Act

Introduced: June 2, 2020 See on congress.gov
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 2, 2020
Read twice and referred to the Committee on Commerce, Science, and Transportation.
Jun 2, 2020
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Combating Egregious Advertising through Sentencing Enhancement Act or the CEASE Act

This bill prohibits and, increases the penalties for, certain commercial practices during the COVID-19 (i.e., coronavirus disease 2019) public health emergency.

Specifically, during such time period, it increases the criminal penalties for false advertising (1) for a first offense from not more than six months in prison and a $5,000 fine to not more than one year in prison and a $50,000 fine and (2) for subsequent offenses from not more than one year in prison and a $10,000 fine to not less than one year or not more than five years in prison and a $250,000 fine. The bill also increases the civil penalty for unfair methods of competition (e.g., creating monopolies) and unfair or deceptive acts or practices (e.g., misleading price claims or sale of defective products) during such time period from $10,000 to $50,000 for a first offense and $250,000 for subsequent offenses.

Additionally, the bill makes it unlawful to engage in unfair or deceptive commercial practices that relate to the COVID-19 pandemic during such time period.

What's happening now June 2, 2020

Read twice and referred to the Committee on Commerce, Science, and Transportation.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
Cite this page click to expand
APA
U.S. Congress. (2026). S. 3862: CEASE Act. 116th Congress. Open America. https://openamerica.io/bill/116-S-3862/
MLA
"S. 3862: CEASE Act." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-S-3862/.
Bluebook (legal)
S. 3862, 116th Cong. (2026), https://openamerica.io/bill/116-S-3862/.
Markdown link
[S. 3862: CEASE Act](https://openamerica.io/bill/116-S-3862/)
Report a problem